#Global Dog Prescription Drugs Market | Explore Tumblr posts and blogs

industryforecastnews · 3 months ago

Text

Flea, Tick And Heartworm Products Market To Reach USD 10.90 Billion By 2030

Flea, Tick And Heartworm Products Market Growth & Trends

The global flea, tick and heartworm products market size is expected to reach USD 10.90 billion by 2030, registering a CAGR of 7.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing an upsurge in developing and launching innovative products. These products can effectively manage parasitic complications in cats & dogs and prove to be a useful parallel option for treatment for pet owners and veterinarians. One such prominent example is flea & tick control collars. These products are just like normal pet collars but contain a specific drug capable of repelling the infestation of fleas, ticks and mosquitoes for some time.

Apart from Seresto by Elanco, other emerging and established players are actively investing in the development of similar collars but utilize novel approaches to enhance infestation control. These launches can also be considered attempts by other companies to capture the market amidst the lawsuit against Seresto Collar. For example, in January 2024, Neogen Corporation launched a collar named Provecta. This collar uses a combination of drugs called deltamethrin and methoprene to inhibit flea and tick growth in dogs and cats. This collar claims to provide six months of protection from fleas, ticks, and mosquitoes.

Furthermore, approvals for injectable products capable of providing long-term animal protection are further intensifying the competitive rivalry. For example, in May 2023, Merck Animal Health received approval for the Bravecto Quantum sale in Australia. This injectable parasiticide can provide over one year of protection against fleas & ticks. Such instances act as catalysts in driving the market by promoting innovative product development that can effectively address the gaps in the prevention & treatment of FTH complications in animals.

Another crucial driver of the demand for these flea, tick and heartworm products is the rising cases of flea and tick infestation in animals worldwide. For example, according to a May 2024 study published in the Veterinary Medicine & Science Journal, the prevalence of fleas and ticks in dogs from the African country of Ethiopia was estimated to be 69.7% and 36.7%, respectively.

Moreover, across the world, in India, the infestation rate of ticks was estimated to be 57.1% in dogs, according to the January 2024 study published in the Acarological Studies Journal. Furthermore, a March 2023 study published in Psyche Journal of Entomology estimated that the prevalence of fleas and ticks in cats from Iran was around 89% and 63%, respectively. This high infestation rate of parasites like fleas and ticks points towards the growing need for effective products to bring this infestation under control, hence boosting market growth.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/flea-tick-heartworm-products-market

Flea, Tick And Heartworm Products Market Report Highlights

Based on product, the treatment products segment accounted for the largest revenue share of 76.00% in 2023. This segment is further divided into products like spot-on, oral pills/chewables, sprays, liquid solutions, shampoos, etc. This spot-on product took the highest share owing to its ease of access, greater absorption, and effective treatment.

Based on type, the prescription segment dominated the with a market share of over 60.00% in 2023. Most flea and tick medications doctors prescribe are taken orally, typically as a tasty, chewable tablet or applied topically for ectoparasites like fleas & ticks.

Based on animal, the canine segment dominated with a share of over 48.00% in 2023 because dogs are the primary species affected by FTH complications, and there are several flea, tick, and heartworm preventative and treatment options available for dogs. The market has grown due to an increasing prevalence of parasite infection in the canine population.

Based on mode of delivery, the topical segment dominated the market in 2023 due to its advantages over oral flea, tick, and heartworm medications. One of the primary advantages of topical flea treatments is that many are not systemically absorbed, which means they do not penetrate the skin barrier or enter a pet's bloodstream. This may be advantageous for animals with a history of adverse drug reactions or who have not previously responded well to oral flea treatments.

Based on parasite, the external parasite segment dominated the market in 2023. This is attributable to the high prevalence of external parasites like fleas and ticks among dogs and cats.

Based on care, the preventive care segment held the dominant revenue share in 2023 and is expected to witness the fastest CAGR over the forecast period. This can be attributed to the fact that veterinarians, as well as animal welfare organizations throughout the world, focus on taking preventive measures for flea, tick and heartworm complications.

Based on distribution channel, the online segment is estimated to grow the most over the forecast period. This growth is driven by factors such as increasing penetration of online pharmacies in under-developed and developing economies, increasing variety of OTC products, and, most importantly, the convenience of procuring flea, tick and heartworm products.

In 2023, North America accounted for the largest market share of 39.71%. The number of Americans who own pets is increasing, which is driving up demand for flea, tick and heartworm products. The region's need for FTH products is also anticipated to grow as the incidence of illnesses caused by fleas, ticks, and heartworms in pets rises.

The Asia Pacific (APAC) market is anticipated to grow at a CAGR of over 8.9% over the forecast period owing to this high transmission rate of vector-borne infections in dogs & cats in the region, and the need for appropriate veterinary medications.

Flea, Tick And Heartworm Products Market Segmentation

Grand View Research has segmented the global flea, tick and heartworm products market based on product, type, animal, mode of delivery, parasite, care, distribution channel, and region:

Flea, Tick And Heartworm Product Outlook (Revenue, USD Million, 2018 - 2030)

Diagnostic Products

Test Kits

Consumables

Treatment Products

Spot on

Oral pills/Chewable

Spray

Liquid Solution

Shampoo

Others

Flea, Tick And Heartworm Products Type Outlook (Revenue, USD Million, 2018 - 2030)

Prescription

OTC

Flea, Tick And Heartworm Products Animal Outlook (Revenue, USD Million, 2018 - 2030)

Canine

Feline

Others

Flea, Tick And Heartworm Products Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)

Topical

Oral

Injectable

Flea, Tick And Heartworm Products Parasite Outlook (Revenue, USD Million, 2018 - 2030)

External Parasite

Internal Parasite

Flea, Tick And Heartworm Products Care Outlook (Revenue, USD Million, 2018 - 2030)

Preventive Care

Therapeutic Care

Flea, Tick And Heartworm Products Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospital/Clinic Pharmacy

Retail Pharmacy

Online Pharmacy

Flea, Tick And Heartworm Product Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

India

China

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Flea, Tick And Heartworm Products Market

Zoetis

Boehringer Ingelheim

Merck & Co. Inc

Virbac

Elanco

Ceva

Promika, LLC

Sergeant's Pet Care Products, Inc.

Adams

BioNote Inc.

Secure Diagnostics Ltd.

iNtRON Biotechnology

Biopanda Reagents Ltd.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/flea-tick-heartworm-products-market

#Flea Tick And Heartworm Products Market #Flea Tick And Heartworm Products Market Size #Flea Tick And Heartworm Products Market Share #Flea Tick And Heartworm Products Market Trends

0 notes

tumblhero · 2 years ago

Text

0 notes

freefestwinner · 4 years ago

Text

Global Dog Prescription Drugs Market Overview, Size, Share and Trends 2025

Summary - A new market study, titled “Global Dog Prescription Drugs Market Insights, Forecast to 2025” has been featured on Wise Guy Reports.

Dog prescription drug is a kind of animal prescription. Animal prescription drug is a prescription drug used to prevent, treat, diagnose, or purposefully regulate an animal's physiology. Animal prescription drugs mainly include: serum products, vaccines, diagnostic products, micro-ecological products, chemicals, antibiotics, biochemical drugs, radioactive drugs and external insecticides, disinfectants, etc.

ALSO READ: https://icrowdnewswire.com/2019/10/18/dog-prescription-drugs-market-2019-global-analysis-forecast-to-2025-market-research-report/

The global Dog Prescription Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dog Prescription Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Dog Prescription Drugs in key regions like North America, Europe, China and Japan, focuses on the consumption of Dog Prescription Drugs in these regions.

This research report categorizes the global Dog Prescription Drugs market by top players/brands, region, type and end user. This report also studies the global Dog Prescription Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Elanco Animal Health

Ceva Sante Animale

MSD Animal Health

Zoetis

Virbac

Dechra

Vetoquinol

Animalcare Group

Ourofino Saude Animal

Boehringer Ingelheim

Dog Prescription Drugs market size by Type

Oral Type

Smear Type

Injection Type

Spray Type

Dog Prescription Drugs market size by Applications

Hospital

Clinic

Others

Market size by Region

North America

United States

Canada

Mexico

Europe

Germany

France

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Central & South America

Brazil

Middle East & Africa

Turkey

GCC Countries

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Dog Prescription Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of Dog Prescription Drugs market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Dog Prescription Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Dog Prescription Drugs submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Dog Prescription Drugs are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dog Prescription Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4451871-global-dog-prescription-drugs-market-insights-forecast-to-2025

About Us: Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)

#Global Dog Prescription Drugs Market

0 notes

jacobwill176 · 4 years ago

Text

Global Dog Prescription Drugs Market Size, Share, Development and Forecast Overview forecast year 2020

A new market study, titled “Global Dog Prescription Drugs Market Insights, Forecast to 2025frastructur” has been featured on …

October 05, 2020

This report studies the global market size of Dog Prescription Drugs in key regions like North America, Europe, China and Japan, focuses on the consumption of Dog Prescription Drugs in these regions.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Elanco Animal Health

Ceva Sante Animale

MSD Animal Health

Zoetis

Virbac

Dechra

Vetoquinol

Animalcare Group

Ourofino Saude Animal

Boehringer Ingelheim

Dog Prescription Drugs market size by Type

Oral Type

Smear Type

Injection Type

Spray Type

Dog Prescription Drugs market size by Applications

Hospital

Clinic

Others

ALSO READ : https://icrowdnewswire.com/2019/10/18/dog-prescription-drugs-market-2019-global-analysis-forecast-to-2025-market-research-report/

Market size by Region

North America

United States

Canada

Mexico

Europe

Germany

France

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Central & South America

Brazil

Middle East & Africa

Turkey

GCC Countries

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Dog Prescription Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of Dog Prescription Drugs market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Dog Prescription Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Dog Prescription Drugs submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Dog Prescription Drugs are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

FOR MORE DETAILS : https://www.wiseguyreports.com/reports/4451871-global-dog-prescription-drugs-market-insights-forecast-to-2025

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)

#Global Dog Prescription Drugs Market

0 notes

merin20 · 4 years ago

Text

What Would Be The Growth Parameters Of The US Animal Drug Compounding Market In The Next 10 Years?

Persistence Market Research published a report on the animal drug compounding market, which considers the U.S. industry analysis 2014 - 2018 and opportunity assessment 2019 - 2029, and projects that the animal drug compounding market is expected to reach ~ US$ 1 Bn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 2 Bn by the end of 2029.

Availability of Alternative Dosage Forms Boosting the Demand for Animal Drug Compounding

Commercially available veterinary drugs often come in a single dosage or strength. Animal drug compounding is able to produce desired drugs with alternate dosage and varied dosage forms, which is not possible during the production of branded drugs. Such types of animal drug compounding involve concentrating the drug in the flavoured gel that is generally applied to the paw or fur of the animal, and is administered by licking. Also, dosage forms such as transdermal drug delivery in animals, are widely accepted in diverse range of animal drug compounding. To cite an example, anti-parasitic drugs for cattle and anti-flea drugs for dogs and cats are most successful transdermal drug delivery transdermal compounded drug products.

Want Insights To US Animal Drug Compounding Market? Ask For Sample! https://www.persistencemarketresearch.co/samples/30058

Lower Availability of Generic Substitutes for Veterinary Drugs

Availability of generic substitutes is much lower for veterinary drugs. Most drugs available for animals for critical diseases are branded drugs. Additionally, currently there is no reimbursement available for veterinary drugs, which indicates that most of the drug expense goes out of the pockets of animal owners. In such circumstances, most pet owners prefer resorting to animal drug compounding that are easily available, cheaper than branded equivalents, and do not require multiple prescriptions.

CNS Drugs to be Most Frequently Dispensed Extemporaneous Medications from Animal Drug Compounding Pharmacies

Central nervous system inflammation is the most common cause of neurological disorders in dogs and cats. Abnormal limb coordination, seizures, behavioral changes, and blindness are cited as the most common abnormalities in dogs and cats with central nervous system inflammation. For instance, according to the International Journal of Pharmaceutical Compounding, central nervous system drugs were the most commonly dispensed medications from animal drug compounding pharmacies with approximately 39% of the total veterinary prescriptions.

Planning To Conclude Your Strategy On A Decisive Note In The US Animal Drug Compounding Market? Glance Through The “Methodology” Implied! https://www.persistencemarketresearch.co/methodology/30058

Absence of Adverse Event Reporting in Animal Drug Compounding

Individual boards of animal drug compounding pharmacies of various states in the U.S. haven’t reported any incidences of adverse events related to animal drug compounding. Furthermore, the U.S. FDA’s adverse drug event reporting system for animals is also not aggregated or comprehensive, and is currently being revised. Since 2001, only 62 compound-related adverse events in animal drug compounding have been reported to the FDA. No definitive trends can be derived out of them. Therefore, absence of adverse event reporting in animal drug compounding will upsurge the demand for animal drug compounding pharmacies.

Unsafe Compounding Practices May Deter the Growth of Animal Drug Compounding

The primary factor restraining the usage of animal drug compounding is unsafe compounding practices, which include compounding contaminations and non-adherence to GMP regulations. This is very prominent across sterile compounding involving injectable drugs and intravenous solutions. Contaminated sterile environments lead to spread of pathogens and fungal infections, and have resulted in various hazards and drug-related deaths, thus dampening the prospects for animal drug compounding. To avoid unsafe animal drug compounding practices, the U.S. FDA has made it mandatory for all outsourcing facilities manufacturing bulk drugs to be inspected and to secure cGMP certification.

How About Knowing The Product/Technology Driving The US Animal Drug Compounding Market Before Investing Therein? Click The “Purchase Now” Button Of Our US Animal Drug Compounding Market Report! https://www.persistencemarketresearch.com/checkout/30058

Key Pharmacies of Animal Drug Compounding

Some key players in the global animal drug compounding market include Hoye’s Pharmacy, Vertisis Custom Pharmacy, Smith Caldwell Drug Store, Sixth Avenue Medical Pharmacy, Doughertys Pharmacy, Triangle Compounding Pharmacy Inc., Medisca Inc., Wedgewood Pharmacy, and Millers Pharmacy.

Explore Extensive Coverage of Persistence Market Research’s Healthcare Industry

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Persistence Market Research Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected]

#US Animal Drug Compounding Market Share #US Animal Drug Compounding Market Demand #US Animal Drug Compounding Market Growth #US Animal Drug Compounding Market Forecast #US Animal Drug Compounding Market Analysis

2 notes · View notes

nanciluke20 · 4 years ago

Text

All about the Gelato near me

The use of medical cannabis these days is contentious, and in recent years the American Medical Association, the MMA, the American Society of Addiction Medicine, and other medical organizations have issued statements opposing its use for medicinal purposes. In general, research says medical marijuana is safe and effective in controlling chronic pain, relieving nausea and vomiting associated with chemotherapy, treating wasting syndrome associated with AIDS, and controlling muscle spasms due to multiple sclerosis and epilepsy. Several studies have indicated that cannabinoids may prevent many types of cancers from spreading and growing, including pancreaticcancer, lung, leukemic, melanoma, oral, lymphoma and other kinds of cancer. A substantial proportion of oncologists support medical marijuana as an option for their own patients. A breed found in Mexico and Central South America. The sativa plant is tall with narrow, serrated leaves. It's THC - the psychoactive-inducing region of the plant - and the consequences are mostly on the mind and emotions. A strain found in Asia and India and grown in the United States. The plant is short and stocky. Indica's effects are mostly physical and some emotional, including relaxation, sedation and pain decrease. The effect in cross pollination of various strains. The effects are often more powerful than the original strain. Unlike many abused drugs, an overdose of marijuana isn't lethal, according to the National Cancer Institute. Although marijuana may be addictive for many, the capacity for forming a dependence on marijuana is lower than some prescription medication and other abused drugs. But, marijuana has unwanted effects. The primary psychoactive chemical in marijuana is THC, or tetrahydrocannabinol, among more than 60 cannabinoids (chemicals unique to marijuana). THC binds to cannabinoid receptors, which can be concentrated in areas of the brain associated with thinking, memory, enjoyment, coordination and time perception. Researchers think that regular cannabis use could have neurotoxin consequences on aging brain structures. A 2012 study at the Proceedings of the National Academy of Sciences found that people who began smoking before age 18, showed a larger decline in IQ and cognitive functioning compared to people who started taking as adults. More: Heavy adolescent users-an typical of four or more occasions a week-who continued to smoke as adults experienced an 8-point IQ fall which couldn't be blamed on booze, other drugs, or less education. The consequences of marijuana may interfere with focus, judgment and balance. Marijuana also suppresses the immune system, which can be detrimental to many people, but helpful for others with certain health conditions. Though marijuana has been proven to decrease pressure within the eyes, a symptom of this illness glaucoma, research has shown that other drugs might be more effective. Studies have produced conflicting results on whether smoking marijuana carries a significant cancer risk. According to the American Cancer Society, global research into the benefits and side effects of chemicals in marijuana is continuing. Some chemicals in marijuana have already been developed into pharmaceuticals. Canada, New Zealand and many countries in Europe have accepted a nasal spray, which uses purified cannabinoids derived from marijuana for the treatment of cancer pain and muscle spasms in multiple sclerosis. The U.S. Food and Drug Administration approved two medications made of synthetic cannabinoids, dronabinol and nabilone, which treat nausea and appetite problems in cancer and HIV patients. Yet the FDA hasn't approved marijuana in its own plant type as a therapy. Living in the rural areas where there are tall grass and bushes everywhere, lies a creature that can make you quite sick from its bite. There are lots of different species of ticks, but only few can infect us with a deadly virus. Emedicine.com-"Ticks are arthropods, such as lions. There are over 800 species of ticks across the world." It is true to say that they are uncontrollable and may attach to anybody of any age. Unfortunately, there is hardly much you can do about the number of these in your lawns and surrounding woodlands. They could travel with several different creatures like; dogs, cats, cattle, raccoons, rabbits and humans. They're attracted to warm, dark areas of the body just visible with the human eye, making them even harder to spot. I believe all could agree that a insect clinging to your skin with no knowledge is rather creepy and scary. I am sure we all recall one time or another child or adult, finding one stuck on us. Emedicine.com-"Ticks will be the leading carriers (vectors) of diseases to individuals in the United States, second only to mosquitoes worldwide." That's a staggering comparison statement considering West Nile Virus is at fault to a lot of lost lives through the years. Along with other life threatening ailments mosquitos' carry pose a higher threat too. In schools nationally, health courses teach children proper behavior to stop Deer Tick bites. There are well known precautions that could be made to prevent them from biting such as; long sleeves, boots, jeans, long sleeves and assessing yourselves, together with children, on a basis after being at the backyard, lawn or anywhere they could possibly dwell. Gently remove the tick with tweezers, making sure to eliminate all of the legs from the skin, wrap it in foil, bring to your doctor to have it cleared as a sign with Lyme disease or not. Deer tick bites left untreated show a red, goal like ring around the face area of the bite, resulting in" Lyme Disease" or"Lyme Borreliosis." This is a serious issue, resulting in a lot of pain that you may wind up in a wheel chair or perhaps bed stricken for days at a time. It takes away the enjoyable aspects of life and can create you're everyday routine unhappy. Most of us know suffering from intense pain isn't a laughing matter, and being nauseous always is a burden inside it itself. This is what this disease places in you're body, sucking on precious time from your life, you are mind too. By the early twentieth century, the growth of the combustion engine and the diesel motor finished the era of commercial sailing ships. The production of steel and iron for cable and boats' hulls further removed natural fibers in marine use. However, hemp does seem to be making a resurgence. And it's about time provided the numerous advantages and benefits of this unusually eco fiber. Many countries are waking up to the worth of hemp. Canada, the uk and Germany all resumed commercial production in the 1990s. In total approximately thirty states produce hemp with China being the largest producer. The Hemp Industries Association has estimated that the North American hemp cloths and fabrics market surpassed $100 million in 2007 and is currently growing at around 10 percent each year. Many doctors treat this disorder with a regiment of antibiotics. This really is the efficient method to cure this disease. Although antibiotics can upset you're gut, affecting appetite severely. Which can lead to weight reduction as the disease progress. Headaches come and go and can consist of wretched migraines. They can be so unforgiving and punishable taking a toll on you every single time. Regular sleeping routines will be continuously interrupted causing chronic tiredness and disrupting ones circadian rhythm. Brutal sharp pains running all of the way up your temples causing pain on your forehead and eyes. Stiffness off your neck, back, legs and joints can make you feel helpless, irritable and tired. Lyme disease can come and go, but for a few it wont let up. In most serious cases, this is categorized as" Persistent Lyme Disease" with people suffering constantly, not in spurts. A lot of people with Lyme disease may not believe cannabis may be one of the more affective long-term medications to help alleviate symptoms. Cannabis is a safer, more calming medicine that can eliminate pain in most forms. Medically, cannabis may be used for a lot of reasons. It fights the aches in your joints and pain during your whole body. The stronger the pressure brings on the more potent medicine. This might be the response to questions about cannabis being an alternative medicine together with the people afflicted by"Lyme Disease" who are looking for other, more natural techniques of healing. Cannabis can provide the energy required to create it through the rough days when your symptoms are large. During the day it can make lying down and falling asleep a beautiful occasion, instead of a bothersome nervous one. After a great night sleep, then you could wake up feeling refreshed instead of tired and sore. At the morning cannabis is an unbelievable way to help loosen your muscles and stiffness out of prior nighttime tossing and turning. The unlucky early sunrises if you woke up sick and tired could really be a thing of the past. Ingesting cannabis will make your appetite more powerful, bringing a much needed nutrition. Walking instead of limping, round the home brings weekends. Additionally for the non-smokers that you could have a yummy, potent and fresh raw medicine of your choice. It's surely true that after polyester came on the scene, natural fibres came under threat experiencing considerable economic hardship during the period from 1960 - 1990. However, post the 1990s, cotton made a tremendous recovery, recapturing market share, and it has continued to show good growth ever since. To find further details please discover more here. Ask you're doctor or physician about medical cannabis on what opinions they have. This might be a breaking point in you're life, helping to dissipate most symptoms of Lyme disease. If all other ways of relieving pain eventually become hopeless cannabis could officially help you. Like a general, Lyme disease truly shows no mercy and no surrender; its time to show it whose going to be the last one standing. See further articles in The Cannabis Times. Getting stoned, getting high, getting baked-all keywords for exactly the same thing. Marijuana has the ability to relax the brain and (if used incorrectly) to blur it. Weed can also relax the body and ease pain, however when used incorrectly, may seriously impair motor skills. Different breeds of medical cannabis have different effects on the body and mind-this is your main reason that"bud tenders" at medical MJ dispensaries urge different breeds for different MMJ patients. Here are five different strains of medical-grade bud and how they influence the mind and body. We chose strains of different types of marijuana, a few indica, a few sativa, some blends, to showcase the varied effects of marijuana breeds on the body and mind. Colorado taxpayers voted to pass Amendment 20 in 2000 opening the doorway for an influx of new legal medical marijuana dispensaries. Over the last several years, the Colorado medical marijuana business is now the fastest growing industry in the state. It had been reported in 2010 which the number of all Denver dispensaries has grown to outnumber the number of Starbucks in town. With this overwhelming variety of new cannabis dispensaries opening across the country, it's hard to know where to get started. Therefore, in the event that you have your Colorado medical marijuana registry card and you are wondering how to obtain the finest Colorado dispensaries, then keep searching for a few handy hints. . .The first step in finding a new medical marijuana dispensary is to identify all the dispensaries that are in close proximity to a place. Google maps is an excellent tool for this job because it will actually overlay location markers should you do a search for something such as"Denver Dispensary". As soon as you have a list of a couple dispensaries in your area, you should start researching each by doing another Google search to their particular title and key words. So search for some thing such as"Denver dispensary review" or just"the finest Denver dispensaries" and you should get you the acceptable results. I recommend using the research from these results to further refine your list down to about 3 of the more interesting dispensaries. You have done the appropriate research and read the reviews, now it's time to go to these top 3 medical marijuana dispensaries to watch for yourself. One thing to remember is that because this sector is still so young there is actuallyn't an industry standard when it comes to how individual Colorado cannabis dispensaries operate. What this means for your is that each Colorado dispensary which you visit will be a unique experience! While many Colorado medicinal marijuana dispensaries do not require appointments to access the medication viewing rooms, it's probably a good idea to call ahead and see if there is going to be a wait to be viewed. When creating your own personal evaluation of a new Colorado cannabis dispensary, there are a couple of things that you are going to want to pay close attention to on your first visit. Your first impression will usually be the living room area where you'll have to provide your Colorado medical marijuana registry card to the person at the counter. After that, you will either be immediately carried to the marijuana room or you'll have to wait till your called back. Wait times are usually very brief, often only taking a couple of minutes. I've found many Denver dispensaries don't have any wait at all during none peak times. The most important part of evaluating a brand new medical marijuana dispensary in Colorado is the experience from the bud screening room. For many people, their very first time walking into this room can be overwhelming. With row after row of glass jars packaged with the best Colorado increased medicinal cannabis, patients simply don't know where to start. Well, here's my tips for dealing with this initial experience. Start with the best. Ask to see the A quality, top shelf, red dot or whatever they call their very best cannabis strains. This will immediately give you an notion of the best that they must offer. Also, don't overlook the lower grades of marijuana. . .sometimes it is possible to locate the very best deal for your buck here. Also be sure to observe the pricing structure. This may be a significant determining factor when choosing a primary caregiver for the long run. Many Denver dispensaries provide separate pricing arrangements for members and nonmembers, so make sure you ask each for certain information. After seeing a few places you will begin to see how the overall decoration and air of Colorado cannabis dispensaries can widely vary place to place. Some dispensaries pose a primitive clinical environment that's somewhat like a doctor's office while some will feel more like you are walking into a buddy's comfortable house. Whatever your preference, there's a Colorado medical marijuana dispensary that's ideal for you. This guide isn't an endorsement for marijuana use. Cannabis is still a drug but it is extremely helpful in treating many people with many aliments. The medical marijuana world is rapidly changing so I strongly recommend reading the official Rules and Regulations for Medicinal use of Marijuana in the Colorado Department of Health before making any decisions concerning the medicinal use of cannabis. In the end the best decisions are informed decisions, so make sure you do comprehensive research on any topic involving your health prior to acting. When it comes to collecting, among the most exciting things you can select to collect are cannabis seeds. These contentious little beans are one of the most finely engineered organic products available, probably just slightly behind roses. The amazing characteristics alongside the sheer number of different strains of seed available make them one of the most interesting and most daunting collections to start.

#Gelato

1 note · View note

digitalconvo · 4 years ago

Text

Addiction Treatments Market : Benefits, Forthcoming Developments, Business Opportunities & Future Investments till 2025

Global Addiction Treatments Market: Snapshot

The menace of drugs has been dogging our society for decades on end now. On one hand, authorities and police are trying to curtail the problem with an iron hand, on the other hand, healthcare institutes and pharmaceutical companies are pulling out all stops to cure addiction.

This has spawned the addiction treatments market which has expanded incrementally over the years. Treatments can happen in different settings and can entail both medication and behavioral therapies. Depending upon the severity of the situation, lengths of treatment can vary. Since, drug addiction is mostly a chronic disorder characterized by occasional relapses, one treatment is usually not enough. It is usually lengthy requiring multiple interventions and time-to-time monitoring.

Some of the common medicines used in treatment of drugs are methadone, buprenorphine, and naltrexone, which are administered to those addicted to opioids. Nicotine preparations in the form of patches, lozenges, gum, and nasal spray and the medications varenicline and bupropion are meant to treat tobacco addiction. Besides, behavioral therapies are leveraged to help addicts cope with drug cravings and thwart a relapse.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=29

The U.S. is one of the main addiction treatments market on account of a sizeable proportion of addicts. However, the market might receive a major setback if the new government manages to pass the bill repealing the Affordable Care Act that provides substantial coverage for drug addiction treatment. This would likely affect nearly 1.3 million people having mental-health and substance abuse disorders as per estimates.

Global Addiction Treatments Market: Overview

The drug epidemic has a severe economic impact in the United States every year. This includes cost incurred to address crime, loss in work productivity, and run rehabilitation programs. The National Institute on Drug Abuse (NIDA) defines drug addiction as a complex condition marked by extreme cravings for drugs and other addictive substances along with excessive seeking for these substances.

The approach for addiction treatment program varies from person to person. The objective of the treatment program is to help patients maintain abstinence from addictive substances and attain effective functioning in both personal and professional life. The treatment programs recommended may be residential or outpatient depending on the severity of the addiction, type of substance, and patient behavior. Hence, the addiction treatment programs include counseling (psychotherapy), outpatient and inpatient programs, and self-help groups.

Outpatient behavioral treatments comprise multidimensional family therapies, cognitive behavioral therapies, and motivational interviewing; while residential treatment programs include staying at a rehabilitation center for a period of about six to twelve months.

Buy this Report @ https://www.tmrresearch.com/checkout?rep_id=29&ltype=S

The report is a valuable tool for understanding the developments of the global addiction treatments market during the forecast period. The report presents a comprehensive analysis of market drivers, market challenges, and opportunities that will impact the progression of the global addiction treatments market for the 2017-2025 period. In this report, market segments and growth indicators are analyzed for historic years based on which projections are made for the forecast period. The report also presents the growth roadmap of leading companies in the market that will lead to changes in the competitive hierarchy.

Global Addiction Treatments Market: Market Segmentation

The global addiction treatments market is segmented on the basis of treatment approach and geography. By treatment approach, medication and therapy are the components of this market. On the basis of geography, North America, Europe, Asia Pacific, and Rest of the World are components of this market.

Global Addiction Treatments Market: Regulatory Drug Approval

The U.S. Food and Drug Administration (FDA) has approved naltrexone, acamprosate, and disulfiram for treating alcohol dependence. Topiramate is a drug that is displaying encouraging results in clinical trials for treating alcohol dependence. Some of the formulations for treating nicotine dependence include chewing gums, lozenges, patches, and spray. Also, the FDA has approved two prescription medications for treating nicotine dependence, namely bupropion and varenicline.

Global Addiction Treatments Market: Drivers and Restraints

The increased use of addictive substances such as alcohol, tobacco, and drugs along with increased marketing initiatives to raise awareness about the detrimental effects of drug addiction is driving the global addiction treatments market. On the other hand, factors such as unwillingness to opt for rehabilitation programs and lack of mental and physical stability of patients during the treatment programs is challenging the growth of this market.

Major Companies in Global Addiction Treatments Market

The report outlines the competitive scenario of the global addiction treatments market with a detailed business profile of the major companies operating in the market. GlaxoSmithKline plc, Reckitt Benckiser plc, Pfizer Inc., and Orasure Technologies are some of the major companies that operate in this market.

Get Table of Content of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=29

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

#Addiction Treatments Market #market report #marketreport #trending

1 note · View note

desaletushki · 2 years ago

Text

Companion Animal Medicine Market Size, Share, Trends And Forecast 2030

The global companion animal medicine market size is anticipated to reach USD 32.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.6% from 2021 to 2028. The key factors driving the market for companion animal medicine include the rising pet population, the prevalence of diseases, and the availability of pet insurance. In Canada for example, 58% of households owned at least one dog or cat in 2020, according to the Canadian Animal Health Institute (CAHI). CAHI also reported a surge in feline vet visits following the start of the COVID-19 outbreak in 2020.

The COVID-19 pandemic notably affected the market for companion animal medicine. The impact included dampened sales, supply chain challenges, operational hurdles, fall inpatient visits, and reduced demand. Elanco for instance reported a 20% decline in revenue during Q2 2020. The company’s companion animal segment, in particular, was adversely impacted by the fall in brands in international markets and those administered in the clinic e.g. vaccines. The company reported a recovery in sales during H2 2020. Vetoquinol on the other hand reported an increase in sales, driven by its essential portfolio including veterinary drugs in 2020 despite limited access to vet clinics and hospitals due to lockdown protocols. Boehringer Ingelheim too registered increased sales in the companion animal segment.

Free Request Sample Report: https://www.grandviewresearch.com/industry-analysis/companion-animal-medicine-market-report

With the rising number of pets across the globe, the trend of pet humanization has gained traction in several key markets. Pet parents are becoming increasingly aware of their pet’s health, treatment, and wellbeing. This has increased the adoption of pet insurance to reduce the financial risks for pet parents. Petplan- the largest pet insurance provider in the U.K. offers insurance policies for various species including dogs, cats, horses, small mammals, birds, reptiles, rabbits, and multi-pet owners. These policies provide coverage for physical and online consultations, prescription medicine, diagnostic tests, surgery, dental injury, cancer treatment, and more.

The rising prevalence of diseases in pets is another key driver expected to contribute to market growth. Parasitic infections from internal and external parasites for example, commonly affect pets. Antibiotics and topical therapies are often prescribed in the case of pyoderma. However, further testing and routine bathing with medicated shampoos may be prescribed in case of chronic or recurring pyoderma. Viv Silky Shampoo by Vivaldis for example is indicated for a range of fungal and bacterial infections including superficial and deep pyoderma.

Companion Animal Medicine Market Report Highlights

The market was valued at USD 15.8 billion in 2020 and is expected to expand at a CAGR of 9.6% during the forecast period

Growing R&D initiatives by major companies is estimated to be a key driver for the market

For instance, Dechra pharmaceuticals commercialized 15 products from its Le Vet R&D pipeline in 2019

Pet humanization is further contributing to increased expenditure on pets including pet medicines

According to APPA U.S. citizens spent about USD 31.4 billion on vet care and products in 2020. The category included expenditure on routine veterinary care, surgical procedures, and pharmaceuticals

The hospital pharmacy segment dominated the market by distribution channel in 2020. The factors contributing to the large share include higher patient footfalls at hospitals and the convenience of buying the necessary medications as soon as the pet is diagnosed

North America held the largest share of about 36% in 2020 owing to well-established veterinary healthcare facilities, rising pet expenditure, and humanization of pets

In Asia Pacific, the market is expected to grow at the fastest rate of over 10% due to the rising pet population and pet health awareness

Key Companies & Market Share Insights

The market is intensely competitive in nature with the presence of many small and large companies. Market players are involved in deploying several strategic initiatives such as R&D, collaborations, product launches, product diversification, expansion of distribution network, and regional expansion. Key players are also involved in mergers and acquisitions and other sales and marketing activities. In August 2021, Elanco for instance acquired Kindred Biosciences for approximately USD 444 million. This supported the company’s access to the dermatology market, complemented its product pipeline, and enhanced R&D capabilities in biologics and monoclonal antibodies. Some of the prominent players in the companion animal medicine market include: Merck & Co., Ceva, Vetoquinol S.A., Zoetis, Boehringer Ingelheim International GmbH, Elanco, Virbac, Bimeda, Norbrook, Calier

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/companion-animal-medicine-market-report

#Companion Animal Medicine Market Size #Companion Animal Medicine Market Share #Companion Animal Medicine Market Forecast #Companion Animal Medicine Market

0 notes

demonic-indulgence-blog · 6 years ago

Text

Counterfeiting A Global Problem

Carisoprodol works by impeding painful sensations between the brain and the nerves. CP: My brain. I take the current day and add 30. It's quite easy as I've practiced using a calendar and math my whole life. Also the main functions, and what comes of having too little or too much of each vitamin in your diet. I asked him about the limp and he said it would have been a lot worse without the big dose of Vitamin I he took regularly. Do you have any idea? A temporal illusion, he states, is the idea that you can change the past. So I have a fondness for crocheting but I am still no rocket scientist but your piece has bought back to mind the years of my mother's majesty and I can not think of it without thinking of her. If your employee tests positive for alcohol you might offer that employee treatment as a condition of continued employment or you can simply act under the zero tolerance policy if you have one. Perhaps we'll have a guilty plea and a quick sentence. Hi Barbara. What a great hub. Various claw enhance manufacturers offer new and interesting colours occasionally, and whether you store great end or on the budget-friendly racks, you’ll be sure to appreciate some guidelines on how to preserve a few dollars on your buys. Surgical treatment is one of the best and fastest option that is easy to cure cataracts in dogs and succeed. Im not sure where you live, but I think Rimmel is the best here in the United Kingdom but is not recommended, pharmacies foundation or concealer. TPG has already partnered with pharmacies and drug manufacturing companies to further solidify the cause. Any questions are seldom asked from the patient by the visual pharmacies regarding their online prescription. The Websites are more likely to sell prescription drugs without legitimate prescriptions. Something that provides customer convenience, helps building customer trust and attracts more clients will increase your revenue. Speaking earlier of Las Vegas, it is a good bet that in the case of James Holmes, answers to legitimate questions will not be forthcoming. If the results are positive for a drug without a valid prescription, illegal or not (alcohol) then you must determine what your course of action will be. This drug is available by prescription only, online pharmacies which means patients need to see their doctor for a full evaluation before the drug is prescribed. Drug Enforcement Administration probe into the sales of painkiller oxycodone found the facility posed a threat to public safety. A survey by the Hay group puts the growth of pharmaceutical sales between 2000 and 2010 at 300 percent. The group urged that importation be fully legalized. These drugs are not usually approved by the FDA and could be dangerous or not effective. In some countries, this is because prescriptions are not required. The other reason for not buying liquid, unsealed powdered or canned products is that, as Amazon expands its warehouse system and adds employees, their packing methods are suffering. The OTC analgesics market is driven by better performance of premium -priced branded products as compared to generic OTC analgesics. Every time I read one, I want to run out and buy the products. It surely doesn't hurt to buy paper towels or toilet paper that saves you money! It has been a trend to buy online, the issue with fraud is now not after the access to legality but the awareness itself. The public has many questions about James Holmes: Was he wasted on drugs? We are an online prescription service offering online prescription medications and mail order drugs for customers throughout the world. “This was especially true for the most vulnerable groups, whose reliance on prescription drugs is highest. When it comes to prices of prescription drugs, no one can beat the US. Vicodin side-effects can include euphoria, paranoia and, in rare cases, hallucinations. My mother struggled and my mother despaired until one afternoon. No one would begrudge anyone from making money, but when making money means potentially endangering others or worse, shouldn't there be a line drawn? It is one of the outstanding features of dieting with Lipotrim. The Internet intermediary liability in India may be frequently invoked against e-commerce websites in India. Again, these are my conjectures, based on limited information and lack thereof. Again, the address associated with the vehicle does not match the physical address where the fire trucks and bomb squads congregated. Virtually none of the respondents said they were aware of any risks associated with taking painkillers for endurance sports. A supposed "unnamed law enforcement source close the investigation" said the notebook, the existence of which has not been confirmed, contained images of stick figures shooting other stick figures. If you need a mobile Twitter app, you don't need anything but the official Twitter iPhone app. So when we receive a new instruction from our doctor, we spend time calling around town to check pricing. Their product line is carried at mega-retailers such as Wal-Mart, Costco, and Target as well as local grocery and convenience stores. There is no indication from the dispatch recordings that he reported his apartment was rigged with explosives, at least prior to 4:00 a.m. LESS THAN 50 CENTS FOR A REFILL THAT WAY! Congress has failed to clarify the situation. It's said he was calm. Answer: Yes. A simple example of this would be hypnosis. They IDed a man who was dressed in black from head to toe, wore a helmet, body armor, and a gas mask.

1 note · View note

suikaaaa-blog · 6 years ago

Text

Read My Mind

Those under age 65 and in the individual and family market can choose from traditional plans and health savings accounts. While the Cost Of Living Allowance for Social Security (COLA) for recipients did not take place in 2010 and 2011, the Medicare prescription changes have helped offset some of the increasing costs in health care. SOME TIS, SUCH AS ED MOORE, A YOUNG MEDICAL DOCTOR, take a slightly more skeptical approach. Patients need to be able to trust in the medicines they take. Withdrawals for qualified medical expenses are not taxable. I believe there are specific items of evidence which, if known, would provoke new questions on top of the witness statements above. They interviewed witnesses, processed evidence, and made public statements. Ostensibly, the disclosure of the court records would be “contrary to public interest,” according to the judge. Lacking meaningful contexts with which to understand such events in their totality the general public is incapable of recognizing the road it is being forced down. As a matter of fact it is absolutely essential to formulate e-health laws in general and Digital India Laws in particular. Alexander belongs to a particular set of Pentagon advisers who consider themselves defense intellectuals, focusing on big-picture issues, future threats and new capabilities. It's In Their Genes: Some breeds -- terriers in particular -- are go-to-ground dogs who dig to find moles, lizards, mice, bugs, and any other critters in the hunt of the day. There is no existing proof that this issue is not a global concern nor are there any warning signs that it has caused mass killings in a certain locality. There are two factors to consider. Although there are no dedicated laws in India regarding telemedicine and its usage yet there are different set of laws that are applicable for different aspects of telemedicine. As on date e-health in India is facing legal roadblocks. A “brag book” is a record of recent accomplishments such as recent awards, letters of praise, recommendation letters, and the like, all of which substantiate or reinforce the claims made in the resume. When asked about that passage in a recent interview, she defended her logic: Being from New York, she claimed, she can recognize Jews. According to a recent Fox News report; for instance, one of the packages allegedly contained a notebook with drawings that outlined the plan for the massacre. I was in search for a good conditioner that would leave my hair extremely soft, I read so many good reviews about the Redken All Soft Conditioner so I decided to get that one from Lookfantastic. You have no way of knowing where these companies are located, where they get their drugs, what is in their drugs, or how to reach them if there is a problem. Though these websites may be “accredited” they are not licensed veterinary offices. The person may feel weak and achy, especially in the bony areas of the face or head. Persistent nausea with an empty feeling in the stomach suggests this remedy, especially if the person feels a little better after warmth and eating food. The person desires warmth and loathes food, tobacco and coffee. What is off-label drug use? To avoid the introduction of toxic chemicals in to your clothes that might affect you in the long run, the use of ionized water is the solution. I hate how the old baby patterns use yarns that we haven't ever heard of though and then don't provide the gauge. How awful about the x-ray machines back then. It was then that she began Colleagues urged Naylor not to publish the book, saying she would destroy her reputation. When the drug is prescribed for either children or adults, it could be used in combination with counselling or other types of treatment. Taking a prescribed drug such as Methylphenidate, can significantly improve the quality of life someone with this condition experiences. Gloria Naylor, a renowned African American writer, seems to defy many of the stereotypes of someone who believes in mind control. For example, in the Batman murders, online canadian pharmacies we have two witnesses who were in the theater and implied there were accomplices. These meds are recommended by the physicians who are associated with visual pharmacies. These OTC analgesics are helpful in pain management; however, they also have adverse effects. Once you have determined that you have met the requirements above, you are ready to set up your HSA.

1 note · View note

your-dietician · 3 years ago

Text

Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

New Post has been published on https://depression-md.com/signs-agreement-with-vetbiolix-for-development-of-piclidenoson-for-pets/

Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

All pre-clinical, clinical, and regulatory development work to be conducted and financially covered by Vetbiolix

Veterinary market has potential for a shorter path to regulatory approval and product revenues

PETACH TIKVA, Israel, June 28, 2021–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats.

Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval for veterinary use.

The canine osteoarthritis market is projected to reach $3 billion by 2024. According to Grand View Research, the broader global companion animal health market is estimated at a value of $20 billion in 2021 and is expected to grow to $27 billion by 2028.

Current treatments for canine osteoarthritis include oral non-steroidal anti-inflammatory drugs (NSAIDs) which only treat symptoms and carry significant harmful side effects, and an injectable disease modifying osteoarthritis drug (DMOAD) that targets the progression of the disease. Piclidenoson, an oral drug that has a favorable safety profile in humans and in animal studies, offers a potentially safe and effective oral treatment for canine osteoarthritis.

“The veterinary market is a significant opportunity where our drugs may have an impact. Both the size of the market and the shorter timelines to regulatory approval have the potential to result in milestone and royalty revenues for Can-Fite. We believe Piclidenoson’s safety and efficacy data in over 1,000 humans, as well as preclinical data from small animals, indicate it may offer relief to the growing number of companion animals with osteoarthritis,” stated Can-Fite VP of Business Development, Dr. Sari Fishman.

Story continues

Matthieu Roquette, President at Vetbiolix commented, “The quality of preclinical and clinical data generated by Can-Fite on Piclidenoson and its pharmacological profile make this highly selective A3 Adenosine Receptor Agonist a drug candidate likely to meet the unmet veterinary medical need to date in the management of osteoarthritis pathology in dogs and cats. Moreover, the mechanism of action of Piclidenoson makes this product a strong candidate for a large spectrum of inflammatory disease indications affecting Pets. We are aiming to enter in veterinary regulatory development by the end of 2022 based on clinical proof of concept data we will generate within the next 12 months.”

In 2019, the U.S. Patent and Trademark Office issued to the Can-Fite patent #10,265,337 titled “Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment” for Piclidenoson in the treatment of osteoarthritis in mammals.

About Vetbiolix

Vetbiolix develops innovative products for treatment and prevention of diseases affecting pets. As pharmaceutical and biotech companies research novel molecules and compounds for human medicine, tests in different species often reveal exciting possibilities for pets. Vetbiolix has developed a unique approach focused on turning this potential into innovative prescription medicines and care products for pets. To date, veterinarians have still few therapeutics and real preventive care products at their disposal that have been specifically developed and approved for pets. Along with a virtual VetBiotech organization, Vetbiolix exclusively focuses on clinical developments of prescription medicines, diagnostics, nutraceuticals and care products for pets, thanks to its qualified external R&D partners in Europe & the US. Vetbiolix is supported by the Eurasanté Bio-Incubator, the northern France health cluster ranked among the top 20 best European incubators fostering pharm/biotech start-up development (Labiotech.eu 2019).

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005218/en/

Contacts

Can-Fite BioPharma Motti Farbstein [email protected] +972-3-9241114

Source link

0 notes

techsciresearch · 4 years ago

Text

Vitamin D Testing Market to grow at a Steady CAGR During the Forecast Period | TechSci Research

Rising prevalence of research and development is driving the growth in Global Vitamin D Testing Market in the forecast period, 2022-2026.

According to TechSci Research report, “Global Vitamin D Testing Market By Product (25-Hydroxy Vitamin D Testing, 1,25-Dihydroxy Vitamin D Testing, 24,25-Dihydroxy Vitamin D Testing) By Application (Clinical Testing, Research Testing) By Technique (Radioimmunoassay, ELISA, HPLC, LC-MS, Others) By Patient (Adult, Pediatric) By Indication (Osteoporosis, Rickets, Thyroid Disorders, Malabsorption, Vitamin D Deficiency, Others) By End User (Diagnostic Laboratories, Hospitals and Clinics, Homecare Settings, Others) By Region, Competition Forecast & Opportunities, 2026”, the global vitamin d testing market is projected to grow at an impressive CAGR in the forecast period, 2022-2026, owing its growth to the attributes like increase in the prevalence of vitamin D deficiency due to lack of exposure to sunlight, low intake of vitamin D diet. Moreover, lack of absorption of food, diseases in liver and kidney, and drugs like phenytoin, rifampin, and phenobarbital is expected to drive the global vitamin D market in the next five years. Furthermore, governmental aid toward the research and development of the vitamin d testing products and related accessories and the clinical trials related to it is anticipated to drive the growth of the market in the forecast period.

Vitamin D is an integral nutrient that is responsible for the control of calcium and phosphate levels in the human body. The vitamin helps in maintaining the cell cycle, fetus development, prevention of neuromuscular disorders and bone disorders. Lack of vitamin D leads to rickets, osteoporosis, cardiovascular disease, cognitive disorders, cancer, autoimmune diseases, and asthma. Vitamin D testing is used to determine if the bone weakness, bone malformation, or abnormal metabolism of calcium that could determine the deficiency or the excess of vitamin D.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Vitamin D Testing Market"

https://www.techsciresearch.com/report/vitamin-d-testing-market/7417.html

The global vitamin d testing market is segmented on the basis of product, application, technique, patient, indication, end user, competitional landscape, and regional distribution. Based on application, the market is further bifurcated into clinical testing, research testing. Research testing is anticipated to assert its dominance over the market in the next five years owing to the increased research and development going on for various diseases. Moreover, clinical testing is anticipated to hold significant share of the market owing the growth to the increased clinical trials, and FD approvals to the various drug developments and testing criteria.

Some of the major competitors in the market are F. Hoffmann-La Roche Ltd., Abbott Laboratories Ltd., Siemens Corporation Ltd., Danaher Corporation Ltd., Quest Diagnostics, Inc., BioMérieux SA, DiaSorin S.p.A., Thermo Fisher Scientific Inc., Quidel Corporation Ltd., Beckman Coulter Inc., Biokit S.A., Tosoh Bioscience, Inc., Qualigen Inc., Diazyme Laboratories, Inc., Hologic, Inc., among others.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7417

Customers can also request for 10% free customization on this report.

“North America is a promising region for the growth of the market. The region has proven its dominance in the historical years, and with the rising prevalence of awareness about the regular screening and presence of major players in the large economies and the available commercialized products in the countries like United States, and Canada. Asia Pacific region is expected to be the fastest growing region due to commercialization of tests in the countries like Japan, and China. Also, demand for the products is rapidly increasing in the countries like India and their developing healthcare industry on the backbone of increased expenditure,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Vitamin D Testing Market By Product Type (Mouthwash/Rinse, Toothpaste, Toothbrush, Dental Chews, Others) By Animal (Dogs, Cats, Horses, Others) By Distribution Channel (Online, Supermarket/hypermarket, Departmental Store, Others) By End User (Residential, Veterinary Hospitals, Private Clinics, Others) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global vitamin d testing and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global vitamin d testing.

Browse Related Reports:

Global Topical Drug Delivery Market By Product (Semi-Solid Formulations, Liquid Formulations, Solid Formulations, Transdermal Products) By Route of Administration (Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery, Nasal Drug Delivery) By End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others) By Distribution Channel (Online vs. Offline) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/topical-drug-delivery-market/7362.html

Global Acne Treatment Market By Therapeutic Class (Retinoids, Antibiotics, Hormonal Drugs, Anti-Inflammatory Drugs, Chemical Peels and Others) By Formulation (Topical Medications, Oral Medications and Injectables) By Type (Prescription Medicines and Over-The-Counter Medicines) By Acne Type (Cystic Acne, Postsurgical/Wound Acne, Comedonal Acne, Inflammatory Acne) By Distribution Channel (Hospitals, Retail Stores, Pharmacies & Drug Stores, and E-Commerce) By Company, By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/acne-treatment-market/7338.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Vitamin D Testing Market #Healthcare #Vitamin D Testing Market #Vitamin D Testing Market Size #Vitamin D Testing Market Forecast

0 notes

techscimarketresearch · 4 years ago

Text

Vitamin D Testing Market to grow at a Steady CAGR During the Forecast Period | TechSci Research

Rising prevalence of research and development is driving the growth in Global Vitamin D Testing Market in the forecast period, 2022-2026.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Vitamin D Testing Market"

https://www.techsciresearch.com/report/vitamin-d-testing-market/7417.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7417

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/topical-drug-delivery-market/7362.html

https://www.techsciresearch.com/report/acne-treatment-market/7338.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Vitamin D Testing Market #Healthcare #Vitamin D Testing Market #Vitamin D Testing Market Size #Vitamin D Testing Market Forecast

0 notes

sandlerresearch · 4 years ago

Text

Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026 published on

https://www.sandlerresearch.org/companion-animal-pharmaceuticals-market-by-indication-infectious-diseases-antibiotics-parasiticides-vaccines-pain-animal-type-dogs-cats-horses-distribution-channel-veterinary-hospitals.html

“The global companion animal pharmaceuticals market is projected to grow at a CAGR of 7.6%.”

The global companion animal pharmaceuticals market is projected to reach USD 18.5 billion by 2026 from USD 12.8 billion in 2021, at a CAGR of 7.6% during the forecast period. Companion animals play an important role in the lives of many, providing a sense of belonging and responsibility. Animal health products, especially pharmaceuticals, are the most widely used products for animal healthcare. They contribute significantly to the health and wellbeing of animals. Companion animal ownership and expenditure have witnessed a significant increase over the years. Pet owners are spending more per pet than ever before. The increasing number of people having pets, emphasis on animal healthcare and vaccination, increasing demand for animal healthcare products, increasing number of veterinary practitioners and their rising income levels in developed economies, increasing prevalence of zoonotic diseases, growth in companion animal adoption, increasing prevalence of animal diseases, and rising demand for pet insurance are some of the factors driving the growth of these markets. However, the limited number of new antibiotics, rising pet care costs, growing resistance to antimicrobials and antibiotics, and rising cost of vaccine storage are restraining the growth of this market to a certain extent.

“The dermatologic diseases segment to grow at the highest CAGR in the companion animal pharmaceuticals market, in the forecast period.”

Based on the prescription of pharmaceuticals for a number of disorders prevailing in animals, the companion animal pharmaceuticals market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic diseases segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of arthritis, rising need for advanced orthopedic drugs, and growing pet population are some of the key factors driving the growth of this segment.

“The dogs segment holds the largest share in the animal type segment, in the forecast period.”

Based on animal type, the companion animal pharmaceuticals market is segmented into dogs, cats, horses, and other companion animals. The dogs segment accounted for the largest market share in 2020. The large share of this segment is attributed to the increasing dog population and rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe.

“Veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market by distribution channel segment in the forecast period”

Based on the distribution channel, the global companion animal pharmaceuticals market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospitals segment is expected to grow at the highest CAGR during the forecast period. The higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries, are some of the key factors driving the growth of this segment.

“North America holds the largest share in the companion animal pharmaceuticals market, by region, in the forecast period”

In 2020, North America accounted for the largest share of the companion animal pharmaceuticals market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the well-established base of animal health industries, the high adoption of companion animals, rising incidence of parasitic infections, the large number of hospitals and clinics, growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is also expected to drive the growth of this market.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:

By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%

By Designation: C-level–35%, Director Level–25%, and Others–40%

By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America – 3%, Middle East & Africa–2%

The prominent players in the global companion animal pharmaceuticals market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Research Coverage:

The report analyzes the market for various companion animal pharmaceuticals and their adoption pattern. It aims at estimating the market size and future growth potential of the global companion animal pharmaceuticals market and different segments such as indication, animal type, distribution channels, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market

Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market.

#Pharmaceutical

0 notes

classyalpacapizza · 4 years ago

Text

Global Veterinary Antibiotics Market Overview 2019 -2026

Description:

Antibiotics are the most important tools in a veterinarian’s toolbox as they cure bacterial disease in animals, without animals suffer or die by devastating diseases like anthrax or pneumonia. The use of antibiotics in animal agriculture helps to grow the demand for safe livestock derived food such as meat, milk and eggs. Global Veterinary Antibiotics Market Dynamics Increasing use of antibiotics in livestock is one of the factors fuelling the global veterinary antibiotics market.

Request Sample of Global Veterinary Antibiotics Market Overview Report @- https://www.99-reports.com/sample-request/veterinary-antibiotics-market/24

According to Food and Drug Administration (FDA), around 12.3 million pounds of medically important antibiotics were sold for use in U.S. livestock and poultry in 2017.In the US, livestock antibiotic use continues to account for about 64% of the sales of medically important antibiotics. In the United States around 80% of all antibiotics are given to cows, pigs, and chickens to make them grow more quickly or as a cheap alternative to keeping them healthy. In 2013, more than 131,000 tons of antibiotics were used in food animals worldwide, and it is expected to rise by 200,000 tons in 2030.In U.K the antibiotic use in pigs about five times higher than in Denmark (46 mg/kg PCU) and the Netherlands (53 mg/kg PCU) and about 25 times higher than in Sweden (11 mg/kg PCU).

Browse Full Global Veterinary Antibiotics Market Overview Report @-https://www.99-reports.com/market-report/veterinary-antibiotics-market#report_Desc

Global Veterinary Antibiotics Market Key Segment

Based on Product type

· Anti parasitic

· Anti bacterial

· Non steroidal anti inflammatory

· Others.

Based on Application

· Farm Animal

· Companion Animals

Download Free PDF Global Veterinary Antibiotics Market Overview Brochure @-https://www.99-reports.com/request-brochure/veterinary-antibiotics-market/24

Currently anti parasitic is the dominant segment and it accounts for approximately XX% of the market, due to the launch of new products and facility expansion for anti parasitic. For instance, in January 2019, Bayer Animal Health have introduced Coraxis (moxidectin) Topical Solution for Dogs, a prescription only, monthly transdermal product that prevents heartworm disease and treats and controls hookworms, roundworms, and whipworms in dogs. Coaxis is a unique addition to the veterinarian's anti parasite toolbox. In June 2018, UC San Diego have introduced new centre for anti parasitic drug discovery and development to address this unmet need in global health. UC San Diego researchers use robotic technology to screen hundreds of thousands of chemical compounds from a variety of sources including drugs abandoned by pharmaceutical companies and marine natural products. Further test the compounds in laboratory experiments and animal health.

Global Veterinary Antibiotics Market Overview Customization @- https://www.99-reports.com/customization/veterinary-antibiotics-market/24

Competitive Analysis

• Bayer

• Boehringer Ingelheim

• Ceva Sante Animale S.A.

• Dechra Pharmaceuticals PLC

• Elanco Animal Health (Eli Lilly Company)

• Merck & Co. Inc.

• Sanofi S.A. Vetoquinol S.A.

• Virbac SA Zoetis Inc.

Conclusion: Thus, changing and growing need to improve efficiency in veterinary market sectors, adoption of veterinary antibiotics is important. Keeping this in mind large number of companies are upgrading their system and providing new avenues to the players in the veterinary antibiotics market.

About Us:

99 Reports is a market research company that provides a solution for all of your analysis needs. Our market reports and skilled services facilitate the organization in taking a business call within the right direction. Utilizing your business alternative with good research combined with an understanding of market patterns, size and demand are some important options of our exploration and market examines. Our main aim is to serve our shoppers with the foremost reliable and correct data.

99- Reports.com

244, Madison Avenue, #1038

New York, NY 10016

Phone: +1844 4452 861

Email: [email protected]

Website: https://www.99-reports.com

#GlobalVeterinaryAntibioticsMarketsize GlobalVeterinaryAntibioticsMarketshare GlobalVeterinaryAntibioticsmarketGrowth GlobalVeterinaryAntibio

0 notes

derivaicontrol · 4 years ago

Text

FDA Approves First Canine Cancer Therapy

MONTREAL–(BUSINESS WIRE)–Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has accepted the initial canine cancer treatment in the U.S. ” PALLADIATM (toceranib phosphate) ” that was designed by Pfizer to take care of mast cell tumors in dogs. Pfizer made the announcement to veterinarians attending the 2009 American College of Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical Association Convention.

“Pfizer Animal Health is pleased to bring the initial canine cancer treatment approved by the FDA to U.S. specialists, their patients and caregivers,” stated George Fennell, vice president, Companion Animal Division, Pfizer Animal Health. “In the weeks and months ahead, Pfizer will present PALLADIA to boarded specialists to enlarge the entire body of clinical experience for this new therapy. The experience gained in this time will enable us to encourage veterinarians more efficiently if we make the product available for purchase in early 2010,” Fennell stated.

Pet caregivers ought to continue to get help from their regional veterinarians about choices for their dogs with cancer, who may then refer appropriate cases to specialists to treatment using PALLADIA.

A new Choice to treat canine mast cell tumors

As stated by the Morris Animal Foundation, cancer is a major cause of death in puppies. 1

Pfizer Animal Health quotes 1.2 million fresh puppy cancer cases are reported at the U.S. every year. 2 Mast cell tumors are the second most frequent tumor type and are frequently viewed as lumps in the skin. These tumors are classified as grade I, II or III, with grade III being the most severe. If not treated, they can spread to other areas of the body such as lymph nodes.

Prescription-only PALLADIA is an oral therapy indicated to treat Patnaik tier II or III recurrent cutaneous mast cell membranes with or without regional lymph node involvement. PALLADIA is owned by the tyrosine kinase inhibitor (TKI) type of compounds. It works by blocking the action of key receptors essential for the development of blood vessels that supply tumors, in addition to receptors crucial for tumor survival.

“PALLADIA is an exciting, new therapy option for dogs with mast cell membranes,” stated Cheryl London, DVM, PhD, board certified medical oncologist and associate professor at The Ohio State University College of Veterinary Medicine.

“At the completion of a PALLADIA clinical research, approximately 60% of dogs had their tumors disappear, shrink or stop growing. Also, we decided that puppies whose tumors reacted to PALLADIA experienced an improved quality of life,” 3 stated Dr. London, who has helped Pfizer Animal Health's Veterinary Medicine Research & Development to develop PALLADIA since 2000.

Further Information about PALLADIA

PALLADIA can be administered at a veterinary clinic or at the home by a puppy's caregiver. PALLADIA isn't appropriate for human use and is only available from the U.S. Adverse events with PALLADIA may be serious but many are light to moderate and are usually manageable. The most frequent side effects of PALLADIA involve the gastrointestinal tract and signs include diarrhea, decreased appetite, lethargy and nausea. Life-threatening negative events are rare but potential and early recognition is critical. Kids should not come in touch PALLADIA. In addition, all people, including children and pregnant women, should avoid direct contact with broken or partially-dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. For particular dosing and prescribing info, see www.palladia-pi.com.

Around Pfizer Animal Health

Pfizer Animal Health, one of six business units of Pfizer Inc (NYSE: PFE), is a world leader in finding and developing innovative animal prescription medicines and vaccines, investing an estimated $300 million yearly. In 2007, Pfizer Animal Health began to enlarge its attention on pet oncology via a $1.1 million award to the Morris Animal Foundation in support of an ongoing national canine tumor biospecimen bank. For more information on how Pfizer helps companion animals to survive longer, healthier lives, or the way Pfizer functions to ensure a safe, sustainable global food supply with healthy livestock, visit www.PfizerAH.com.

Concerning the American College of Veterinary Internal Medicine (ACVIM)

The ACVIM is the national certifying organization for veterinary experts in big and small animal internal medicine, cardiology, neurology and oncology. The mission of the ACVIM would be to boost animal and human health by advancing veterinary internal medicine through education, instruction and discovery. For more information, please visit www.ACVIM.org.

Two Pfizer Animal Health Market Research, New York, New York, data on record

3 London CA, Malpas PB, Wood-Follis SL, et al.. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor after surgical excision. Clinical Cancer Research. Published online May 26, 2009 as 10.1158/1078-0432. CCR-08-1860.

0 notes